POST Online Media Lite Edition


Hyperion appoints Daniel G. Welch to board of directors

Staff writer |
San Francisco, Ca., USA - August 29, 2012, San Francisco, Ca., USA - Hyperion Therapeutics, a pharmaceutical company, announced that it has named Daniel G. Welch to its board of directors.

Article continues below

Mr. Welch currently serves as Chairman, Chief Executive Officer and President of InterMune, Inc., a public biotechnology company based in Brisbane, California. Mr. Welch has more than 30 years of experience in the biotechnology and pharmaceutical industries.

Prior to InterMune, Mr. Welch served as Chairman and Chief Executive Officer of Triangle Pharmaceuticals, Inc., from 2002 to 2003. From 2000 to 2002, he served as President of the pharmaceutical division at Elan, plc., and from 1987 to 2000, Mr. Welch served in various senior management roles at Sanofi-Synthelabo (now Sanofi-Aventis) and its predecessor companies Sanofi and Sterling Winthrop.


What to read next

ITC Holdings Corp. Appoints Welch to Chairman
Welch Allyn: Eric Allyn member of board of directors
BIO-key appoints Cecilia Welch as CFO